BioMedNewsBreaks Archive - Page 176 of 244

ThursdaySep 16, 2021 9:35 am

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Announces Partnership Digital Therapeutics Alliance

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, is joining the Digital Therapeutics Alliance. A nonprofit association of industry leaders, the alliance is dedicated to driving awareness and adoption of digital therapies. MINDCURE announced that, as part of the alliance, the company is committed to providing value and reimbursement, policy and regulation, and awareness to educate the broader health-care industry about the benefits of including new technologies in current treatment regimes. Collaboration with the alliance is a strategic move as MINDCURE works to position iSTRYM, its proprietary software application, as…

TuesdaySep 14, 2021 2:55 pm

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leveraging Partnerships to Save Patients’ Lives, Broaden Product Pipeline

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, recently announced a cooperation agreement with Roche Pharmaceuticals China, a subsidiary of Roche Holdings AG, to explore novel medical solutions. Under the agreement, “both parties plan to utilize AnPac Bio’s Cancer Differentiation Analysis (‘CDA’) cancer detection technology and Roche’s FoundationOne CDx to create a solution that customers with a high cancer risk level as assessed by CDA and later diagnosed with cancer can receive a personalized CDx precision medical test for therapy selection. The parties aim to help benefit the general population while lowering costs…

TuesdaySep 14, 2021 2:36 pm

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) Is Frontrunner in Support of Psychedelic-Assisted Therapy

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF), a leader in advanced proprietary technology and research for psychedelics, is devoted to building access to safe, science- and evidence-backed psychedelic-assisted therapies globally. “The company has filed a provisional patent application for its pharmaceutical-grade synthetic ibogaine to be used in clinical research and anticipates developing that in conjunction with its software-as-a-service (‘SaaS’) platform iSTRYM,” reads a recent article. iSTRYM is designed to help physicians and patients manage psychiatric medications using smart “digital therapeutics” technology. On August 10, MCURF announced an agreement with Dr. Ken Weingardt to provide consulting services as a senior clinical…

MondaySep 13, 2021 3:30 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Poised to Offer Solution to Rising Challenge Facing Global Health Systems

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company, offers next-generation technological solutions for the neurology market. The company’s two FDA-cleared devices, NeuroCap(TM) and NeuroEEG(TM), allow quick and reliable EEG testing in minutes and by any health care worker, not only specialized neurological technicians, bringing brain diagnostics to settings in which neurological testing was previously impossible or difficult. “As we learn more about COVID-19, it is becoming increasingly clear that neurological care in the post-COVID world will be crucial,” reads a recent article. This revelation comes amid findings by scientists who are starting to collect more and more…

MondaySep 13, 2021 11:05 am

BioMedNewsBreaks – Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Announces Engagement of Oak Hill Financial for Investor Relations, Advisory Services

Avricore Health (TSX.V: AVCR)(OTCQB: AVCRF) today announced that it has appointed Oak Hill Financial Services Inc. to provide the company with investor relations and advisory services. Toronto-based Oak Hill is a financial services provider that assists companies in enhancing their corporate profile. Under the agreement, Avricore will pay Oak Hill a fee of $12,000 per month for an initial three months. Oak Hill will provide services such as drafting marketing materials and reaching out to its Canadian investor network to expand Avricore’s visibility in the financial community. “We are really excited by Oak Hill’s track record of success in our sector,…

FridaySep 10, 2021 10:24 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at H.C. Wainwright 23rd Annual Global Investment Conference

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today announced that its president and CEO Eric. A. Adams will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The event is slated to be held virtually from Sept. 13-15, 2021. Adams’ presentation will be available on-demand beginning at 1:00 p.m. ET on Sept. 13, accessible from the H.C. Wainwright events platform at HCW Events. An archived replay will be available on the company’s website immediately following the conference for a period of 90 days. In addition, InMed’s management team will be conducting…

WednesdaySep 08, 2021 12:06 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Participate at H.C. Wainwright 23rd Annual Global Investment Conference

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, today announced its participation at the H.C. Wainwright 23rd Annual Global Investment Conference. Vivos CEO Kirk Huntsman will be presenting at the event beginning at 7:00 a.m. EDT on Monday, Sept. 13, 2021. Interested institutional or retail investors should visit https://ibn.fm/VL1jk to register for the conference and may listen to the company’s presentation online at https://ibn.fm/YuFWj. A replay of the presentation will be available via the Investor Relations page of the company’s website. To…

WednesdaySep 08, 2021 10:46 am

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) to Participate in H.C. Wainwright Global Investment Conference

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF), a leader in advanced proprietary technology and research for psychedelics, has announced that it will featured at the upcoming H.C. Wainwright 23rd annual Global Investment Conference. The three-day conference is scheduled to begin Sept. 13 and runs through Sept. 15, 2021. MINDCURE president and CEO Kelsey Ramsden will present an overview of the company on Sept. 13, 2021, at 7 a.m. ET. The presentation will be available for interested viewers for 90 days following the conference. To view the presentation, visit https://ibn.fm/whfnm To view the full press release, visit https://ibn.fm/IyoMF About Mind Cure Health…

TuesdaySep 07, 2021 2:34 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Positioned as First Mover in Psychedelics Space

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) CEO Greg McKee was recently hosted by Oren Klaff on the Dealmaker Podcast. The interview, which illuminated Tryp Therapeutics’ operations and McKee’s personal story on how he ended up as the CEO, offered some great insights into the future of the psychedelics space, along with what ordinary people can do to take the industry to the next level. A recent article reads, “Mr. McKee cited the benefits that come with the use of psilocybin in treating pain. For one, he discussed their effectiveness without the accompanying risk of addiction associated with opioids. He also…

TuesdaySep 07, 2021 9:32 am

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Ownership Increase in Subsidiary Holding

AnPac Bio-Medical Science (NASDAQ: ANPC) subsidiary AnPac Bio-Medical Science (Lishui) Co. Ltd. has increased its holding in AnPai (Shanghai) Healthcare Management Consultant Co. Ltd., one of its subsidiaries; the increase came after approval was granted by the company audit committee and board of directors. The company announced that in late August 2021 it finalized the share structure registration amendment with the local Administration Management Bureau. Before making the decision, company officials conducted rigorous due diligence that included obtaining financial and legal audits and appraisals by a qualified appraiser. AnPac Bio-Medical Science is a biotechnology company with operations in China and…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Announces Partnership Digital Therapeutics Alliance

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leveraging Partnerships to Save Patients’ Lives, Broaden Product Pipeline

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) Is Frontrunner in Support of Psychedelic-Assisted Therapy

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Poised to Offer Solution to Rising Challenge Facing Global Health Systems

BioMedNewsBreaks – Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Announces Engagement of Oak Hill Financial for Investor Relations, Advisory Services

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at H.C. Wainwright 23rd Annual Global Investment Conference

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Participate at H.C. Wainwright 23rd Annual Global Investment Conference

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) to Participate in H.C. Wainwright Global Investment Conference

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Positioned as First Mover in Psychedelics Space

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Ownership Increase in Subsidiary Holding

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search